Skip to content

    Research Use Only

    This site is an educational resource for research compounds. We do not endorse human consumption of any compound. BodyHackGuide and BHG Labs share common ownership; we rank every vendor on the same public methodology, and we earn a commission on purchases through our links. By entering, you confirm you are 21 years of age or older and agree to our Terms & Privacy Policy.

    100K+ researchers trust BodyHackGuide — Join r/BodyHackGuide
    Research Database

    Research Compound Wiki

    Evidence-based profiles for 242 research compounds — peptides, nootropics, SARMs, and growth-hormone secretagogues — with PubMed citations, mechanisms of action, dosing ranges, half-lives, and verified vendor pricing.

    242
    Compounds
    3,708,075
    PubMed Studies
    65
    Categories

    The BodyHackGuide wiki indexes research compounds across 65 major categories. Every profile pulls live study counts from PubMed, dosing data from published protocols, and pricing from verified third-party-tested vendors. Compounds are tagged by research stage (preclinical, Phase I–III, approved) and research field (longevity, metabolic, cognitive, recovery, etc.). Nothing here is medical advice — everything is for research purposes only.

    Most-Studied Compounds

    Ranked by PubMed citation count — the compounds with the deepest peer-reviewed literature base.

    1. 01
      Collagen PeptidesProtein
      967084 studies
    2. 02
      CalciumMineral
      854847 studies
    3. 03
      Grape Seed ExtractHerbal
      489243 studies
    4. 04
      GlutathioneRecoveryt½ Short: on the order of minutes for intravenous glutathione (intact GSH is cleared rapidly from plasma and cellular uptake of intact GSH is limited). Oral bioavailability is low, so tissue glutathione levels depend mainly on endogenous synthesis from cysteine, glycine, and glutamate rather than on the half-life of administered GSH.
      203023 studies
    5. 05
      Vitamin AVitamin
      111748 studies
    6. 06
      ProbioticsSupplement
      105565 studies
    7. 07
      ChromiumMineral
      93196 studies
    8. 08
      ManganeseMineral
      85480 studies
    9. 09
      L-TryptophanNootropic
      80432 studies
    10. 10
      MolybdenumMineral
      76143 studies

    Free 2026 Peptide Cheat Sheet — 50 pages, PDF

    Reconstitution math, concentration charts, half-lives, and vendor trust tiers. The reference we wish we had on day one.

    Download Free

    Adaptogen (17)

    Research compounds in the Adaptogen family, compiled from peer-reviewed literature and clinical trial registries.

    Anabolic Peptide (2)

    Short chains of amino acids that signal specific receptors. Research peptides range from healing compounds like BPC-157 and TB-500 to growth-hormone secretagogues like Ipamorelin and Tesamorelin, and GLP-1 agonists like Semaglutide and Retatrutide.

    Antioxidants (2)

    Research compounds in the Antioxidants family, compiled from peer-reviewed literature and clinical trial registries.

    Bioregulator Peptide (2)

    Short chains of amino acids that signal specific receptors. Research peptides range from healing compounds like BPC-157 and TB-500 to growth-hormone secretagogues like Ipamorelin and Tesamorelin, and GLP-1 agonists like Semaglutide and Retatrutide.

    Carotenoid (5)

    Research compounds in the Carotenoid family, compiled from peer-reviewed literature and clinical trial registries.

    Cofactor (1)

    Research compounds in the Cofactor family, compiled from peer-reviewed literature and clinical trial registries.

    Cognition, Mood & Neuroprotection (1)

    Research compounds in the Cognition, Mood & Neuroprotection family, compiled from peer-reviewed literature and clinical trial registries.

    Cognitive (3)

    Research compounds in the Cognitive family, compiled from peer-reviewed literature and clinical trial registries.

    Controlled Substances (1)

    Research compounds in the Controlled Substances family, compiled from peer-reviewed literature and clinical trial registries.

    Energy & Performance (1)

    Research compounds in the Energy & Performance family, compiled from peer-reviewed literature and clinical trial registries.

    DMHA

    Energy & PerformanceHistorical pharmaceutical; no modern clinical trials

    DMHA (octodrine) - chemically 2-amino-6-methylheptane, also sold as 2-aminoisoheptane or 1,5-dimethylhexylamine - is an aliphatic-amine central nervous system stimulant and a close structural analog of DMAA (1,3-dimethylamylamine).

    t½ Not formally characterized in humans. After ingestion, octodrine is rapidly metabolized to heptaminol, which becomes the predominant compound detected in blood and urine within hours [PMID:39401652]. Users commonly report perceptible stimulant effects lasting roughly 3-6 hours, but this is anecdotal rather than measured pharmacokinetics. 75-200 mg per dose (anecdotal pre-workout range; ~75,000-200,000 mcg). Historical pharmaceutical unit dose was 8-33 mg. No approved or clinically validated dose exists.
    PreclinicalView Profile

    Enzyme (1)

    Research compounds in the Enzyme family, compiled from peer-reviewed literature and clinical trial registries.

    Essential Nutrient (1)

    Research compounds in the Essential Nutrient family, compiled from peer-reviewed literature and clinical trial registries.

    Flavonoid (4)

    Research compounds in the Flavonoid family, compiled from peer-reviewed literature and clinical trial registries.

    Foundational (13)

    Research compounds in the Foundational family, compiled from peer-reviewed literature and clinical trial registries.

    GH Secretagogue (1)

    Research compounds in the GH Secretagogue family, compiled from peer-reviewed literature and clinical trial registries.

    GLP-1 / Glucagon Dual Agonist (1)

    Research compounds in the GLP-1 / Glucagon Dual Agonist family, compiled from peer-reviewed literature and clinical trial registries.

    Growth Hormone (1)

    Endocrine signaling molecules and analogues studied across metabolic, reproductive, and performance contexts. Includes thyroid analogues, insulin sensitizers, and HPTA-restoring compounds.

    Growth Hormone / IGF-1 Axis (11)

    Endocrine signaling molecules and analogues studied across metabolic, reproductive, and performance contexts. Includes thyroid analogues, insulin sensitizers, and HPTA-restoring compounds.

    Hepatoprotective Flavonolignan (1)

    Research compounds in the Hepatoprotective Flavonolignan family, compiled from peer-reviewed literature and clinical trial registries.

    Herbal (8)

    Research compounds in the Herbal family, compiled from peer-reviewed literature and clinical trial registries.

    Hormonal (1)

    Research compounds in the Hormonal family, compiled from peer-reviewed literature and clinical trial registries.

    HCG

    HormonalFDA-approved

    Human chorionic gonadotropin (hCG) is a 237-amino-acid glycoprotein hormone produced naturally during pregnancy by trophoblast cells of the developing embryo, beginning as early as 6-8 days after conception and peaking between weeks 8-11 of gestation at concentrations of 50,000-300,000 mIU/mL maternal serum.

    t½ Approximately 24-36 hours (terminal elimination). Clearance is biphasic: an initial distribution phase of roughly 6-11 hours followed by a terminal phase averaging ~33 hours. This is far longer than pituitary LH (~20-30 minutes), owing to the beta-subunit C-terminal peptide (CTP) and heavy sialylation. Peak plasma concentration occurs ~6-12 hours after SC or IM injection, and a single dose exerts biological effects for roughly 5-7 days. Elimination is primarily renal.
    PreclinicalView Profile

    Hormone (1)

    Endocrine signaling molecules and analogues studied across metabolic, reproductive, and performance contexts. Includes thyroid analogues, insulin sensitizers, and HPTA-restoring compounds.

    Hormone Support (2)

    Endocrine signaling molecules and analogues studied across metabolic, reproductive, and performance contexts. Includes thyroid analogues, insulin sensitizers, and HPTA-restoring compounds.

    T3/T4 Thyroid Blend

    Hormone SupportComponents are FDA-approved prescription drugs (levothyroxine and liothyronine); the fixed-ratio synthetic T3/T4 combination product is investigational/unapproved as sold and is framed here strictly for research use only (RUO).

    A T3/T4 blend pairs two real, FDA-approved thyroid hormones - levothyroxine (T4) and liothyronine (T3) - in a single product, intended to more closely mimic the thyroid gland's natural output than T4 alone.

    t½ T4 (levothyroxine): approximately 6-7 days in euthyroid adults (longer in hypothyroid, shorter in hyperthyroid states). T3 (liothyronine): approximately 1 day (~18-24 hours), which is why T3 is dosed multiple times daily or as a slow-release preparation. Component-split and physician-set, not a fixed self-dose: T4 (levothyroxine) approximately 75-150 mcg/day and T3 (liothyronine) approximately 5-20 mcg/day divided - both titrated to labs (TSH, free T4, free T3), individualized by weight, age and cardiac status. Not a self-dosing recommendation.
    PreclinicalView Profile

    Hormones & Endocrine (Non-GH) (3)

    Endocrine signaling molecules and analogues studied across metabolic, reproductive, and performance contexts. Includes thyroid analogues, insulin sensitizers, and HPTA-restoring compounds.

    Immune & Inflammation (2)

    Research compounds in the Immune & Inflammation family, compiled from peer-reviewed literature and clinical trial registries.

    Injury, Repair & Recovery (2)

    Research compounds in the Injury, Repair & Recovery family, compiled from peer-reviewed literature and clinical trial registries.

    BPC-157

    Injury, Repair & RecoveryPreclinical

    BPC-157 (Body Protection Compound-157) is a synthetic pentadecapeptide consisting of 15 amino acids (Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val) derived from a partial sequence of human gastric juice protein BPC.

    t½ Short plasma half-life. The first formal preclinical ADME study reported an elimination half-life under ~30 minutes after IV/IM dosing in rats and dogs, with linear dose-proportional kinetics (PMID: 36588717); a 2026 biopharmaceutical review confirms this sub-30-minute plasma half-life and highlights a pharmacokinetic-pharmacodynamic disconnect, as biological effects persist for hours to days (PMID: 42198317). No full human pharmacokinetic study has been published; twice-daily dosing is empirical/community-standard rather than PK-derived. 200-500 mcg subcutaneous 1-2x daily (community protocols); 1-10 mcg/kg in animal studies
    214 studiesView Profile

    Isothiocyanate (1)

    Research compounds in the Isothiocyanate family, compiled from peer-reviewed literature and clinical trial registries.

    Liver Support (1)

    Research compounds in the Liver Support family, compiled from peer-reviewed literature and clinical trial registries.

    Liver/Digestive (1)

    Research compounds in the Liver/Digestive family, compiled from peer-reviewed literature and clinical trial registries.

    Longevity (4)

    Research compounds in the Longevity family, compiled from peer-reviewed literature and clinical trial registries.

    Longevity & Cellular Health (2)

    Research compounds in the Longevity & Cellular Health family, compiled from peer-reviewed literature and clinical trial registries.

    Metabolic (3)

    Research compounds in the Metabolic family, compiled from peer-reviewed literature and clinical trial registries.

    Metabolic & Weight Loss (7)

    Research compounds in the Metabolic & Weight Loss family, compiled from peer-reviewed literature and clinical trial registries.

    Mineral (8)

    Research compounds in the Mineral family, compiled from peer-reviewed literature and clinical trial registries.

    Mitochondrial Peptides (1)

    Short chains of amino acids that signal specific receptors. Research peptides range from healing compounds like BPC-157 and TB-500 to growth-hormone secretagogues like Ipamorelin and Tesamorelin, and GLP-1 agonists like Semaglutide and Retatrutide.

    Mitochondrial Support (1)

    Research compounds in the Mitochondrial Support family, compiled from peer-reviewed literature and clinical trial registries.

    Myostatin Inhibitor (1)

    Research compounds in the Myostatin Inhibitor family, compiled from peer-reviewed literature and clinical trial registries.

    Nootropic (7)

    Cognitive-enhancing compounds studied for memory, focus, learning, and neuroprotection. Includes racetams, cholinergics like Alpha-GPC, amino-acid derivatives like L-Theanine, and plant adaptogens like Bacopa Monnieri.

    Nootropic Adaptogen (1)

    Cognitive-enhancing compounds studied for memory, focus, learning, and neuroprotection. Includes racetams, cholinergics like Alpha-GPC, amino-acid derivatives like L-Theanine, and plant adaptogens like Bacopa Monnieri.

    Nootropic Lipid (1)

    Cognitive-enhancing compounds studied for memory, focus, learning, and neuroprotection. Includes racetams, cholinergics like Alpha-GPC, amino-acid derivatives like L-Theanine, and plant adaptogens like Bacopa Monnieri.

    Nootropic Peptide (9)

    Short chains of amino acids that signal specific receptors. Research peptides range from healing compounds like BPC-157 and TB-500 to growth-hormone secretagogues like Ipamorelin and Tesamorelin, and GLP-1 agonists like Semaglutide and Retatrutide.

    Nootropics (27)

    Cognitive-enhancing compounds studied for memory, focus, learning, and neuroprotection. Includes racetams, cholinergics like Alpha-GPC, amino-acid derivatives like L-Theanine, and plant adaptogens like Bacopa Monnieri.

    Other (8)

    Specialty research compounds spanning lipid modulators, longevity molecules, mitochondrial cofactors, and emerging translational targets.

    B7-33

    OtherPreclinical

    B7-33 is a single-chain, 26-amino-acid peptide engineered as a functionally selective agonist of the relaxin family peptide receptor 1 (RXFP1), designed to recapitulate the therapeutic activity of human H2 relaxin — the endogenous peptide hormone that is naturally elevated during pregnancy and has broad cardioprotective, vasodilatory, and anti-fibrotic effects.

    t½ In vitro serum-stability half-life is approximately 6 minutes; B7-33 is rapidly degraded (a lipidated analog extended this to ~60 minutes in the same assay). Human in vivo pharmacokinetics are unpublished, and rapid clearance is expected for a small linear peptide (Praveen et al. 2023, PMID 37047588). 500-4000 mcg subcutaneous per injection (community/self-report research doses; most commonly ~1000 mcg / 1 mg once daily). No validated human dose exists - all figures are empirical extrapolations from rodent pharmacology.
    11 studiesView Profile

    Peptides (1)

    Short chains of amino acids that signal specific receptors. Research peptides range from healing compounds like BPC-157 and TB-500 to growth-hormone secretagogues like Ipamorelin and Tesamorelin, and GLP-1 agonists like Semaglutide and Retatrutide.

    Performance (3)

    Research compounds in the Performance family, compiled from peer-reviewed literature and clinical trial registries.

    Performance & Recovery (1)

    Research compounds in the Performance & Recovery family, compiled from peer-reviewed literature and clinical trial registries.

    Pharmaceutical (2)

    Research compounds in the Pharmaceutical family, compiled from peer-reviewed literature and clinical trial registries.

    Polyamine (1)

    Research compounds in the Polyamine family, compiled from peer-reviewed literature and clinical trial registries.

    Polyphenol (4)

    Research compounds in the Polyphenol family, compiled from peer-reviewed literature and clinical trial registries.

    Protein (1)

    Research compounds in the Protein family, compiled from peer-reviewed literature and clinical trial registries.

    Recovery (17)

    Research compounds in the Recovery family, compiled from peer-reviewed literature and clinical trial registries.

    Reproductive Hormone (1)

    Endocrine signaling molecules and analogues studied across metabolic, reproductive, and performance contexts. Includes thyroid analogues, insulin sensitizers, and HPTA-restoring compounds.

    Senolytics (1)

    Research compounds in the Senolytics family, compiled from peer-reviewed literature and clinical trial registries.

    Skin & Hair (6)

    Research compounds in the Skin & Hair family, compiled from peer-reviewed literature and clinical trial registries.

    Skin / Cosmetic (1)

    Research compounds in the Skin / Cosmetic family, compiled from peer-reviewed literature and clinical trial registries.

    Skin, Hair & Aesthetics (3)

    Research compounds in the Skin, Hair & Aesthetics family, compiled from peer-reviewed literature and clinical trial registries.

    Sleep (1)

    Research compounds in the Sleep family, compiled from peer-reviewed literature and clinical trial registries.

    Sleep & Circadian (2)

    Research compounds in the Sleep & Circadian family, compiled from peer-reviewed literature and clinical trial registries.

    Stilbene Polyphenol (1)

    Research compounds in the Stilbene Polyphenol family, compiled from peer-reviewed literature and clinical trial registries.

    Supplement (1)

    Research compounds in the Supplement family, compiled from peer-reviewed literature and clinical trial registries.

    Supplies (1)

    Research compounds in the Supplies family, compiled from peer-reviewed literature and clinical trial registries.

    Tanning Peptide (1)

    Short chains of amino acids that signal specific receptors. Research peptides range from healing compounds like BPC-157 and TB-500 to growth-hormone secretagogues like Ipamorelin and Tesamorelin, and GLP-1 agonists like Semaglutide and Retatrutide.

    Vitamin (9)

    Research compounds in the Vitamin family, compiled from peer-reviewed literature and clinical trial registries.

    Weight Loss (9)

    Research compounds in the Weight Loss family, compiled from peer-reviewed literature and clinical trial registries.

    herb (4)

    Research compounds in the herb family, compiled from peer-reviewed literature and clinical trial registries.

    Browse Full Database

    Filter by category, research phase, and research field — or use the search bar at the top of the page.

    Sort
    Category
    Phase
    Field

    242 compounds in database

    BPC-157

    Injury, Repair & RecoveryPreclinical

    BPC-157 (Body Protection Compound-157) is a synthetic pentadecapeptide consisting of 15 amino acids (Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val) derived from a partial sequence of human gastric juice protein BPC.

    t½ Short plasma half-life. The first formal preclinical ADME study reported an elimination half-life under ~30 minutes after IV/IM dosing in rats and dogs, with linear dose-proportional kinetics (PMID: 36588717); a 2026 biopharmaceutical review confirms this sub-30-minute plasma half-life and highlights a pharmacokinetic-pharmacodynamic disconnect, as biological effects persist for hours to days (PMID: 42198317). No full human pharmacokinetic study has been published; twice-daily dosing is empirical/community-standard rather than PK-derived. 200-500 mcg subcutaneous 1-2x daily (community protocols); 1-10 mcg/kg in animal studies
    214 studiesView Profile

    Pinealon

    NootropicsPreclinical

    Pinealon is a synthetic tripeptide — glutamyl-aspartyl-arginine (Glu-Asp-Arg, or EDR) — developed by the St Petersburg Institute of Bioregulation and Gerontology (IBG) under the leadership of Professor Vladimir Khavinson, the dominant figure in what is collectively known as the "Russian short-peptide bioregulator" school of research.

    t½ Not formally characterized in humans. Short regulatory peptides of this class are cleared from plasma within minutes; the Khavinson framework proposes durable downstream gene-expression effects that outlast the brief dosing window, which is the stated rationale for pulsed cycling rather than continuous dosing. Subcutaneous (primary route): 2-10 mg/day, typically 3-5 mg, in pulsed 10-20 day cycles, 2-4 cycles/year. Intranasal: 150-800 mcg per nostril daily. Research use only; oral dosing is not recommended because the peptide is largely degraded by GI proteases.
    21 studiesView Profile

    B7-33

    OtherPreclinical

    B7-33 is a single-chain, 26-amino-acid peptide engineered as a functionally selective agonist of the relaxin family peptide receptor 1 (RXFP1), designed to recapitulate the therapeutic activity of human H2 relaxin — the endogenous peptide hormone that is naturally elevated during pregnancy and has broad cardioprotective, vasodilatory, and anti-fibrotic effects.

    t½ In vitro serum-stability half-life is approximately 6 minutes; B7-33 is rapidly degraded (a lipidated analog extended this to ~60 minutes in the same assay). Human in vivo pharmacokinetics are unpublished, and rapid clearance is expected for a small linear peptide (Praveen et al. 2023, PMID 37047588). 500-4000 mcg subcutaneous per injection (community/self-report research doses; most commonly ~1000 mcg / 1 mg once daily). No validated human dose exists - all figures are empirical extrapolations from rodent pharmacology.
    11 studiesView Profile

    FOXO4-DRI

    RecoveryPreclinical

    FOXO4-DRI is a synthetic 34-amino-acid D-retro-inverso peptide designed to disrupt the interaction between the FOXO4 transcription factor and p53, with the specific goal of inducing apoptosis selectively in senescent cells.

    t½ Not established in humans; no published human pharmacokinetic data. The D-retro-inverso construction confers resistance to human proteases, which in preclinical models extends the in vivo half-life from minutes (typical for comparable L-amino-acid peptides) to hours ([Baar et al., 2017](https://pubmed.ncbi.nlm.nih.gov/28340339/)). No validated human dose. Self-report: 2-15 mg SC per dose (typically 5 mg), pulsed 3-7 days every 2-6 months; no human PK data. The 5 mg/kg figure seen in some sources is a mouse research dose (Baar 2017), not a human dose.
    8 studiesView Profile

    PE-22-28

    NootropicsPreclinical

    PE-22-28 is a synthetic seven-amino-acid peptide (sequence PAGASRLLLLTGEIDLP derivative, commonly truncated to PE-22-28 as shorthand for "position 22-28" within the parent humanin-family sequence) that was designed as an analog of Humanin with specific interest in activity at glutamate transporter regulation and cytoprotective signaling relevant to depression and neuroprotection.

    t½ Not characterized in humans. As a small 7-amino-acid peptide a short plasma half-life is expected; in mice the parent peptide spadin lost antidepressant activity by about 7 hours after a single dose, while modified analogs (e.g., G/A-PE 22-28) extended the behavioral effect to roughly 21-23 hours [PMID:28955242]. 250-2000 mcg subcutaneous per dose (empirical research-chemical community range; no clinically validated human dose exists; effective preclinical rodent doses were far lower, ~3 mcg/kg).
    1 studiesView Profile

    DMHA

    Energy & PerformanceHistorical pharmaceutical; no modern clinical trials

    DMHA (octodrine) - chemically 2-amino-6-methylheptane, also sold as 2-aminoisoheptane or 1,5-dimethylhexylamine - is an aliphatic-amine central nervous system stimulant and a close structural analog of DMAA (1,3-dimethylamylamine).

    t½ Not formally characterized in humans. After ingestion, octodrine is rapidly metabolized to heptaminol, which becomes the predominant compound detected in blood and urine within hours [PMID:39401652]. Users commonly report perceptible stimulant effects lasting roughly 3-6 hours, but this is anecdotal rather than measured pharmacokinetics. 75-200 mg per dose (anecdotal pre-workout range; ~75,000-200,000 mcg). Historical pharmaceutical unit dose was 8-33 mg. No approved or clinically validated dose exists.
    PreclinicalView Profile

    HCG

    HormonalFDA-approved

    Human chorionic gonadotropin (hCG) is a 237-amino-acid glycoprotein hormone produced naturally during pregnancy by trophoblast cells of the developing embryo, beginning as early as 6-8 days after conception and peaking between weeks 8-11 of gestation at concentrations of 50,000-300,000 mIU/mL maternal serum.

    t½ Approximately 24-36 hours (terminal elimination). Clearance is biphasic: an initial distribution phase of roughly 6-11 hours followed by a terminal phase averaging ~33 hours. This is far longer than pituitary LH (~20-30 minutes), owing to the beta-subunit C-terminal peptide (CTP) and heavy sialylation. Peak plasma concentration occurs ~6-12 hours after SC or IM injection, and a single dose exerts biological effects for roughly 5-7 days. Elimination is primarily renal.
    PreclinicalView Profile

    Riboflavin

    VitaminPreclinical

    Riboflavin (vitamin B2) is a water-soluble vitamin that serves as the precursor to two universal flavoprotein cofactors — flavin mononucleotide (FMN) and flavin adenine dinucleotide (FAD) — which together serve as electron-carrying prosthetic groups in more than 90 human enzymes including Complex I and Complex II of the mitochondrial electron transport chain, the acyl-CoA dehydrogenases of fatty acid β-oxidation, glutathione reductase (the enzyme that regenerates reduced glutathione for antioxidant defense), methylenetetrahydrofolate reductase (MTHFR, the critical folate cycle enzyme), pyridoxine-5-phosphate oxidase (PNPO, which converts dietary B6 vitamers to active PLP), and kynurenine monooxygenase in the tryptophan-to-NAD+ pathway.

    PreclinicalView Profile

    T3/T4 Thyroid Blend

    Hormone SupportComponents are FDA-approved prescription drugs (levothyroxine and liothyronine); the fixed-ratio synthetic T3/T4 combination product is investigational/unapproved as sold and is framed here strictly for research use only (RUO).

    A T3/T4 blend pairs two real, FDA-approved thyroid hormones - levothyroxine (T4) and liothyronine (T3) - in a single product, intended to more closely mimic the thyroid gland's natural output than T4 alone.

    t½ T4 (levothyroxine): approximately 6-7 days in euthyroid adults (longer in hypothyroid, shorter in hyperthyroid states). T3 (liothyronine): approximately 1 day (~18-24 hours), which is why T3 is dosed multiple times daily or as a slow-release preparation. Component-split and physician-set, not a fixed self-dose: T4 (levothyroxine) approximately 75-150 mcg/day and T3 (liothyronine) approximately 5-20 mcg/day divided - both titrated to labs (TSH, free T4, free T3), individualized by weight, age and cardiac status. Not a self-dosing recommendation.
    PreclinicalView Profile

    Last updated: August 18, 2026

    Weekly research drop

    Get the research before it hits Reddit.

    One email per week — new compound profiles, dosing protocols, vendor alerts, and the studies that actually replicate. No fluff.

    Unsubscribe anytime. We never share your email.

    © 2026 BodyHackGuide · Research purposes only.

    Shop BHG Labs · 20% off with BHG20